Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study

Lignende værker

• Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
  af: Tanaka, Yoshiya, et al.
  Udgivet: (2020)
• Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
  af: Takeuchi, Tsutomu, et al.
  Udgivet: (2016)
• Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
  af: Takeuchi, Tsutomu, et al.
  Udgivet: (2019)
• Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
  af: Koike, Takao, et al.
  Udgivet: (2011)
• Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
  af: Tanaka, Yoshiya, et al.
  Udgivet: (2016)